NuCana plc: NuCana Reports First Quarter 2021 Financial Results and Provides Business Update
Additional Clinical Data Announcements and Study Initiations Expected in 2021
EDINBURGH, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
As of March 31, 2021, NuCana had cash and cash equivalents of £78.6 million compared to £87.4 million as of December 31, 2020. NuCana continues to advance its various clinical programs and reported a net loss of £9.8 million for the quarter ended March 31, 2021, as compared to a loss of £4.0 million for the quarter ended March 31, 2020. Basic and diluted loss per share was £0.19 for the quarter ended March 31, 2021, as compared to £0.12 per share for quarter ended March 31, 2020.
Investegate |NuCana plc Announcements | NuCana plc: NuCana Reports First Quarter 2021 Financial Results and Provides Business Update investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7
th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.
Event: 7
Date: May 4 to May 5, 2021
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our p
NuCana plc: NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.
Event: 7
Date: May 4 to May 5, 2021
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana s robus
NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors
NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3 -dATP
Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana s ProTides in clinical development were presented. Summaries of the posters are described below.